Zacks Analyst Blog Highlights: Johnson & Johnson, ViroPharma, Theravance, Cubist Pharmaceutical and Pfizer - Press Releases
For Immediate Release
Chicago, IL – January 4, 2010 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson (JNJ), ViroPharma (VPHM), Theravance (THRX), Cubist Pharmaceutical (CBST) and Pfizer (PFE).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Thursday’s Analyst Blog:
Pipeline Setback for J&J
Johnson & Johnson (JNJ) has received yet another setback related to its pipeline candidate ceftobiprole, a broad-spectrum antibiotic − aiming the methicillin-resistant Staphylococcus aureus (MRSA) − for the treatment of complicated skin infections and nosocomial pneumonia. Johnson and Johnson had licensed the drug from Swiss drug company Basilea Pharmaceuticals in 2005.
Johnson and Johnson received a complete response letter (CRL) from the US Food and Drug Administration (FDA), delaying the approval process further. According to the FDA, there were many flaws in the trials due to which the company has been asked to conduct new studies to evaluate the drug's safety and effectiveness. Johnson and Johnson intends to discuss its future course of action related to ceftobiprole with the FDA shortly.
The new drug application (NDA) for ceftobiprole has been pending since May 2007. The approval has been getting delayed due to the presence of protocol related issues from initial stages. In November 2008, the FDA issued a CRL recommending additional site audits to be conducted. Following this, the company completed the audits through a third party, the results of which were submitted in June this year.
Ceftobiprole’s path to approval has not been smooth in the EU either. The review process has been halted until a Good Clinical Practice inspection is done. An opinion by the EU Committee for Medicinal Products for Human Use is anticipated in the first quarter of 2010. Given the repetitive delays in the approval process in both the US and EU, Basilea filed an arbitration claim against Johnson and Johnson in Feb 2009 seeking damages. The latest delay would increase the claims in the arbitration process.
On approval, ceftobiprole will have to compete with several established drugs, which include ViroPharma’s (VPHM) Vancocin, Theravance’s (THRX) Vibativ, Cubist Pharmaceutical’s (CBST) Cubicin, Pfizer’s (PFE) Zyvox and Tygacil.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com
The preceding article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
